Spare the rod and spoil the eye

G B Arden, R L Sidman, W Arap and R O Schlingemann

Br. J. Ophthalmol. 2005;89;764-769
doi:10.1136/bjo.2004.062547

Updated information and services can be found at:
http://bjo.bmj.com/cgi/content/full/89/6/764

These include:

References
This article cites 83 articles, 49 of which can be accessed free at:
http://bjo.bmj.com/cgi/content/full/89/6/764#BIBL

3 online articles that cite this article can be accessed at:
http://bjo.bmj.com/cgi/content/full/89/6/764#otherarticles

Rapid responses
You can respond to this article at:
http://bjo.bmj.com/cgi/eletter-submit/89/6/764

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

- Vision Research (671 articles)
- Other ophthalmology (2378 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to British Journal of Ophthalmology go to:
http://www.bmjjournals.com/subscriptions/
Spare the rod and spoil the eye

G B Arden, R L Sidman, W Arap, R O Schlingemann

This review presents a new unified view of the pathogenesis of three common causes of acquired retinal degenerative disease—diabetic retinopathy, age related macular degeneration, and retinopathy of prematurity. In these three conditions, angiogenesis has a predominant role in the development of sight threatening pathology. Angiogenesis is controlled by among other factors the expression of vascular endothelial growth factor (VEGF), which in turn is regulated by absolute and relative lack of oxygen. The severe pathological manifestations of these three conditions are not part of a general underlying disease process because they are peculiar to the eye, and the profound hypoxia that develops in normal retina during dark adaptation (rod driven hypoxia) is an adequate and elegant additional factor to explain their pathogenesis. A large number of experimental reports support this conclusion, although rod driven anoxia is not generally considered as a causal factor in ocular disease. However, the hypothesis can be critically tested, and also suggests novel methods of treatment and prevention of these conditions that may be simpler and more inexpensive than current therapies and that have a smaller potential for adverse effects.

DIABETIC RETINOPATHY

Histopathology of the condition peculiar to the eye

Diabetes, experimental and clinical, selectively damages retinal microvessels. Elsewhere, the diabetic state causes thickening of capillary basement membrane, but only in retinal blood vessels is there loss of pericytes, and swelling and damage to capillary endothelial cells that result in the capillary dropout, microaneurysms, leakage, cellular damage, and new blood vessel growth that characterises DR. This indicates that local factors unique to the retina provoke DR, although retina is often considered “an approachable part of the brain.” The main difference between retina and brain tissue is, of course, the photoreceptors.

Energy requirements of photoreceptors

Their signal transduction mechanism, found in no other neuron, is very energy demanding. In darkness the surface membrane of the rod outer segment is leaky, and water and sodium enter, to be extruded by pumps in the inner segment. Light seals the leaks in the outer segment, reduces or stops the dark current and promptly halts the pump action, reducing metabolism and oxygen uptake. The maximum magnitude of the dark current under strict dark adapted conditions indicates that the rod circulates its entire cytosol volume in 30 seconds, and this process produces more heat and consumes more oxygen than any function in any other cell. Although the

Abbreviations: AGEs, advanced glycation end products; ARM, age related maculopathy; ARMD, age related macular degeneration; CNV, choroidal neovascularisation; DR, diabetic retinopathy; PRP, panretinal photocoagulation; ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor
retina has a double blood supply from the central artery and from the choroid, the photoreceptor layers are avascular, and the oxygen supply is normally barely sufficient. This explains why dark adapted sensitivity in normal people begins to drop when there is a slight reduction of inspired oxygen, equivalent to ascending to 3000 feet (914 metres), and loss of dark adaptation is the first symptom in a variety of pathological conditions, ranging from polycythaemia vera to partial carotid occlusion, before other functions fail.

**Retinal anoxia in dark adaptation is present in normal eyes**

Experiments with oxygen microelectrodes in normal eyes show a precipitous drop in partial oxygen pressure (pO2) as the microelectrode passes from the level of the choroidal blood vessels to fall to a minimum in the vicinity of the rod mitochondria and the photoreceptor cell synapses in the outer plexiform layer. In dark adapted eyes this minimum pO2 is zero, but even during a brief flash of light it reaches 30 mm Hg. Unlike other brain cells, rods can apparently function in such ultra low oxygen environments but their remarkably intense activity in darkness reduces the pO2 of the inner retina, a region served by blood vessels that penetrate inward from the vitreal surface but do not actually reach the rod cells. Therefore, when rods operate at maximum activity, a relative anoxia may develop in the inner portions of the retina in disease states with less than optimal oxygen supply.

**Relative impairment of oxygen supply in early (grade 0 and 1) DR**

Clinical DR appears to develop years after the condition is diagnosed. But during the preclinical period, although the fundus is normal (stage 0), psychophysical and electrophysiological experiments demonstrate that anomalies are developing, especially in rod vision (reviewed by Arden). It has been shown that several of these losses can be promptly, though only partially, reversed by inhaling oxygen from a face mask. Therefore, even at stage 0, there must be a degree of oxygen lack in the retina of people with diabetes. Thus, the loss of dark adaptation in people with diabetes at stage 0 is explicable. Diabetes causes a series of slight changes in the circulation: glycosylated haemoglobin has a Michaelis-Menten curve shifted slightly to the right, basement membranes thicken, and red blood cell walls stiffen slightly, reducing ease of transport through the capillaries. In most tissues, these modifications would be of little consequence, but the retina has very little reserve capacity, and slight reductions in oxygen supply would tend to decrease the pO2. This cannot fall below the zero level found in the region of the rod mitochondria, but proximal and distal to this point pO2 will be reduced. This concept is supported by findings in diabetic cats, where retinal oxygen tension is reduced relative to normal, even in regions with no fluorescein angiographic evidence of actual capillary dropout.

**Production of cytokines in diabetic retina enhanced by hypoxia**

Hyperglycaemia is the first signal to trigger the onset of DR and the cascade of metabolic and biochemical changes.

Hyperglycaemia is associated with apoptosis of neuronal and vascular cells in the retina. High levels of intracellular glucose cause, among other changes, a state of “pseudohypoxia” in retinal cells. (Pseudo)hypoxia may upregulate factors such as vascular endothelial growth factor A (VEGF-A). VEGF is a prime regulator of angiogenesis and vascular permeability (reviewed by Ferrara), but may have vasoprotective and neuroprotective functions as well. Evidence is available for a role of VEGF-A in the early stage of DR, as retinal VEGF expression by activated Müller cells is increased a few weeks after the onset of diabetes in rats. Intracellular pseudohypoxia, high levels of glucose and advanced glycation end products (AGEs) all induce increased VEGF expression in cells in vivo and in vitro. We suggest that in preclinical DR, the increased anoxia associated with complete dark adaptation is a crucial and necessary driving force of VEGF upregulation, in synergy with the consequences of chronic hyperglycaemia. Therefore, even in the preclinical phase of diabetic retinopathy, dark adapted rods are instrumental in the increase of VEGF expression. VEGF overexpression may reflect a stress response enabling survival of vascular and neuronal cells, but it also induces early blood-retinal barrier breakdown, leucocyte adhesion to retinal vessels, swelling of endothelial cells, and proliferation of endothelial cells.

Once this increase is established, repeated insults of endothelial apoptosis and reactive proliferation probably cause replicative senescence of endothelial cells resulting in the capillary dropout seen in clinical DR, which, by itself, may leads to a vicious circle of ischaemia, VEGF production, endothelial swelling and capillary non-perfusion, reinforcing the production of anoxia. This scheme of events can easily be envisaged against the background of rod induced anoxia acting as an independent driving force. Later, when clinical DR is established, and widespread vascular leakage, capillary dropout, and neovascularisation can be seen, the anoxia associated with DR is evident (see fig 1). The part played by VEGF-A and its receptors in this clinical stage is very well documented.

**Evidence that DR is caused by local anoxia**

Evidence is plentiful for the suggestion that “rod driven anoxia” triggers the changes that cause DR. As predicted, DR does not occur in patients who have diabetes and retinitis...
pigmentosa because rod outer segments are reduced in this condition. Proliferative DR may even regress in the presence of retinal degenerations such as retinitis pigmentosa. In the mitochondrial disorder MIDD 3243, which begins in adult life, diabetes is characteristic, and DR commonly occurs unless a retinal degeneration also develops. Some people with longstanding diabetes (types 1 and 2) develop no signs of DR at all. In a group of these, it has been shown that the upregulating effect of anoxia on blood white cell VEGF production is greatly reduced. However, the best evidence of the importance of anoxia is (i) the success of the common treatment of DR, panretinal photocoagulation, which was introduced to destroy retinal tissue thought to be liberating "toxins," but which may work simply by destroying enough rods to increase retinal P02, and (ii) the recent report that breathing oxygen from nasal tubes for 3 months improves visual acuity and partially reverses the appearance of the macula in cases of diabetic maculopathy. Such treatment only provides <10% more oxygen to the retina. An alternative strategy, light adaptation during sleep, could reduce the oxygen requirement by ~50% and should therefore be at least as effective.

**Other causes of DR, and predictions arising from the new hypothesis**

Of course several systems contribute to diabetic retinopathy. The effects of glucose and insulin are well known, and the polyol pathway, and pseudohypoxia that is associated with NAD-NADH levels also can cause retinal damage. In experimental oxygen induced retinopathy, knockout of insulin receptors, which are indirectly necessary for VEGF activity, reduces vascularisation by 50%, but knockout of rods in mice prevents any vascular proliferation in this model. Almost the only time human rods ever dark adapt (and maximise their oxygen needs) in our electrically lit modern environment is during sleep. Our hypothesis predicts that if people with diabetes and grade 0–I retinopathy were to sleep in light levels of 1–10 cd/m², sufficient light would pass through the lids to protect against DR. (Consideration of the quantity of light required can be found in the paper by Arden.) Another testable prediction is that elderly people with diabetes who suffer from sleep apnoea would have considerably more DR than those who do not.

**RETNOPATHY OF PREMATUREITY**

Rod driven anoxia is also the probable cause of ROP. In a well known mouse model of ROP, pups are placed in 75% oxygen from postnatal day P7 to P12. For the first two thirds of this period the eyelids are still closed, the rod outer segments have just begun to form, and the retina is growing and becoming vascularised. However, the hyperoxia results in an underdevelopment of retinal vasculature. Return to normal air at P12 coincides with the rapid development of rod outer segments, an increased retinal oxygen demand, and a large rise in retinal VEGF, so that by P17–21, a prominent proliferative retinopathy develops. However, if the same experiment is performed with mutant mice in which photoreceptor cells degenerate as their rod outer segments are differentiating, no proliferative retinopathy is found. Thus, in this model the activity or presence of rods is necessary for ROP to develop.

Despite great advances in paediatric care, ROP remains a relatively frequent complication of prematurity. It is customary to maintain premature infants in well illuminated intensive care units, though ordinary care units typically are maintained in reduced illumination. By analogy with the mouse experiments, our hypothesis suggests this is precisely the wrong arrangement. When neonates are maintained in a high oxygen environment, they should be exposed to as little light as possible to encourage growth of the retinal vessels. Red light (wavelength >660 nm) is scarcely absorbed by retinal rods; general and local illumination with red light emitting diodes should suffice for all necessary manipulations. When the neonate is returned to a normal air environment, the room should be brightly lit, so that the oxygen demand of the still immature eye is minimised. Brief trials would show whether this regime results in less ROP. Experimental evidence exists supporting our hypothesis. In the mouse model, ROP is less prominent in litters kept continuously in darkness than those kept exposed to anoxia in light. In a multicentre trial in neonates, goggles absorbing 97% of ambient illumination were fitted at random to half of the babies. In this trial, the investigators’ hypothesis that bright light is harmful in neonates could not be confirmed, as predicted by our hypothesis. That this trial did not show an opposite effect, consistent with our hypothesis, may be because of the amount of light passing through the goggles and the eyelids: with eyes open, retinal illumination was at photopic levels (4 cd/m²) behind the goggles. Because eyelids in neonates absorb less light than in adults, even with the lids closed, the retinal illumination in the “goggled” babies could have been sufficient for a light adapted state and have a protective effect against rod driven anoxia. In fact, the percentage of “goggled” babies who had ROP was slightly higher when the goggles were fitted early. Thus, the results of this clinical trial are at least consistent with our hypothesis.

**AGE RELATED MACULAR DEGENERATION**

**Pathology**

Age related maculopathy is a multifactorial condition. Though there is a genetic component, the rapidly increasing prevalence suggests the importance of environmental factors, and this is also indicated by histopathological studies (see below). The natural history shows that after the age of 55, increasing numbers of people develop large “soft” drusen, and the number of these increase with time. The drusen are seen in the posterior pole, often in a ring peripheral to the macula. The drusen are the clinically visible indicators of a collection of abnormal material between Bruch’s membrane and the retinal pigment epithelium (RPE) and Bruch’s membrane and the choroid, known as basal laminar and basal linear deposits, respectively. The RPE also becomes loaded with lipofuscin granules, resulting from phagocytosis and incomplete digestion of rod outer segment fragments. The volume of shed outer segments is ~2 μm³ per rod per year (Young and Bok) and ~30 outer segments per each RPE cell. Analysis of the material contained in drusen shows it contains highly oxidised lipids, suggesting their formation by reactive oxygen species in senescent RPE cells that can no longer properly digest phagocytosed rod outer segments. This failure leads to the accumulation of the deposits in both the “dry” and “wet” forms of ARMD. At the same time, abnormalities occur in the choroid. Thus, ARMD appears to be another disease whose manifestations are caused by local retinal factors. Visual function is affected early in the condition. Dark adaptation is slowed and less complete even in the early stages, and blue cone vision is also affected. Like DR, there is an asymptomatic “preclinical” stage but during this stage, drusen can be seen, pigment irregularities develop, and subtle losses of rod and cone function occur. The histologically verified loss of rods in the region of their highest density suggested that the condition is caused by the death of rods, but at a comparable stage there is also evidence of an obstructive barrier between choroid and RPE which hinders the diffusion of oxygen from the choroid. Abnormal biochemical and immunoocyto- logical findings have been reported at this phase. With the loss of rods, irregularities and patchy diminution of choroidal
bran

 blood flow may be seen in ageing eyes.66 67 81 The causal relations of these several findings are obscure. The primary disorder may be a defect in the RPE. Curcio82 raises the possibility that rod death leads to loss of a trophic factor necessary for normal cone function. However, in various other forms of night blindness, with absent or very reduced rod function, macular degeneration does not occur as an early event. The early stage (now often called age related maculopathy, ARM) occurs with little obvious symptomatology, but after some time, subjective visual disturbance occurs, associated with a change in retinal appearance. In the “dry” form, a limited retinal geographic atrophy eventually occurs. The fovea can be spared. In other cases, there is growth of new vessels from the choroid through Bruch’s membrane into the subretinal space, local oedema, and leakage (choroidal neovascularisation (CNV)). At this stage there is metamorphopsia, considerable reduction in acuity and obvious retinal damage. At such a stage the condition is often termed age related macular degeneration.

Cytokines in age related maculopathy

In development, and during adult life, the RPE controls the vascularisation of the choroids.1 There is a normal strong polarisation of the secretion of VEGF basolaterally,84 and this paracrine relation with the choriocapillaris1 is disturbed by changes associated with ageing.85 In ageing, Bruch’s membrane thickens and becomes lipid laden,82 decreasing hydraulic conductivity and aqueous diffusion to the choroid.1 Even in the earliest stages of ARM, there may be retinal and RPE hypoxia because of the high metabolic requirements of the retina. Any diminution of VEGF secretion into the choroid will cause choriocapillaris atrophy, which indeed is observed in aged human eyes (reviewed by Witmer et al4), and reduce the oxygen supply to the adjacent RPE and retina. Thus ageing changes may enter a vicious circle, with alteration in RPE function eventually leading to further relative atrophy of choriocapillaris, the deposition of basal deposits, the relative impermeability of Bruch’s membrane, and documented loss of rod and blue cone function. At this clinical stage considerable retinal and RPE hypoxia upregulates VEGF, but transfer to the choriocapillaris is so reduced that a higher critical concentration may develop in the outer retina, or proximal to Bruch’s membrane, triggering choroidal neovascularisation.86 87 Alternately, the anoxia can cause death of RPE and retina in geographic atrophy. Although many factors contribute to this sequence of change,89 critical participants are (i) abnormally metabolised material shed from the rods (responsible for the barrier to fluid transfer), and (ii) the extreme metabolic demands of rods (contributing heavily to anoxia and VEGF upregulation). This suggests that were rods to be absent the changes associated with ARM would develop more slowly.

Effects of lasering and panretinal photocoagulation on ARM

A small number of scattered laser burns in ARM reduces drusen, and can stabilise retinal function.90 91 92 The Choroidal Neovascularisation Prevention Trial (CNPT)93 also determined this, but the immediate high incidence of neovascularisation following their protocol led to termination of patient recruitment. However, after 5 years, the patients’ vision was not worse than controls, so that some retardation in development of ARMD must have occurred. The longest small trial shows that the production of “wet” ARMD is reduced 8 years after lasering. The mechanism whereby such light lasering removes drusen (at least temporarily), and apparently arrests the progress of retinal degeneration is not fully established. However, there is evidence that many more retinal burns, applied to people with much milder ARM, can have beneficial outcome. In people with type 2 diabetes ARM occurs at a similar frequency to normal controls.94 However, after panretinal photocoagulation (PRP) there is a marked reduction in the prevalence of wet and dry ARMD and there is much anecdotal evidence to the same effect. All this suggests that an important factor in the development of ARM may be a relative anoxia in the outer part of the retina/RPE complex. The reported increase in cytokine formation95 96 is of course consistent with a local relative anoxia. The success of two differing anti-VEGF therapies97 100 in improving vision and fundus appearances in patients with ARM also indicates the importance of this cytokine in the development of the disease, and provides further indications of the importance of relative anoxia. Anoxia would necessarily be worse during periods of dark adaptation and, as in DR, it is possible that the condition would progress more slowly if such periods were avoided.

In summary, we propose that the huge numbers of peripheral rods are major driving factors in hypoxic retinopathies, and propose light adaptation during sleep, or early prophylactic inactivation or laser culling as a therapy.

ACKNOWLEDGEMENTS

Supported by the Edward en Marianne Blaauw Fonds.

References


www.bjophthalmol.com


